The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Control of the Immune Response by Pro-Angiogenic Factors
Open accessAbstract
The progressive conversion of normal cells into cancer cells is characterized by the acquisition of eight hallmarks. Among these criteria, the capability of the cancer cell to avoid the immune destruction has been noted. Thus, tumors develop mechanisms to become invisible to the immune system, such as the induction of immunosuppressive cells, which are able to inhibit the development of an efficient immune response. Molecules produced in the tumor microenvironment are involved in the occurrence of an immunosuppressive microenvironment. Recently, it has been shown that vascular endothelial growth factor A (VEGF-A) exhibits immunosuppressive properties in addition to its pro-angiogenic activities. VEGF-A can induce the accumulation of immature dendritic cells, myeloid-derived suppressor cells, regulatory T cells, and inhibit the migration of T lymphocytes to the tumor. Other pro-angiogenic factors such as placental growth factor (PlGF) could also participate in tumor-induced immunosuppression, but only few works have been performed on this point. Here, we review the impact of pro-angiogenic factors (especially VEGF-A) on immune cells. Anti-angiogenic molecules, which target VEGF-A/VEGFR axis, have been developed in the last decades and are commonly used to treat cancer patients. These drugs have anti-angiogenic properties but can also counteract the tumor-induced immunosuppression. Based on these immunomodulatory properties, anti-angiogenic molecules could be efficiently associated with immunotherapeutic strategies in preclinical models. These combinations are currently under investigation in cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
The immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981
Effector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer
Pagès, F., Berger, A., Camus, M., Sanchez-Cabo, F., Costes, A., Molidor, R., Mlecnik, B., Kirilovsky, A., Nilsson, M., Damotte, D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051424 · Cited by 2,135 · cited 1×
“For example, in colorectal cancer, Pagès and Galon have demonstrated that the absence of pathological signs of early metastatic invasion (vascular emboli, lymphatic invasion, and perineural invasion) was correlated with the presence of effector memory T cells (CD45RO) within the tumor and a better overall and disease-…”
BackgroundRegulation of immune responses by L-arginine metabolism
Bronte, V., & Zanovello, P. (2005) · Nature Reviews Immunology · doi:10.1038/nri1668 · Cited by 1,775
Huang, Y., Yuan, J., Righi, E., Kamoun, W. S., Ancukiewicz, M., Nezivar, J., Santosuosso, M., Martin, J. D., Martin, M. R., Vianello, F., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1215397109 · Cited by 1,099
Research works printed but not linked: 77
- Hanahan, 2000, The hallmarks of cancer, Cell, 100, 57, 10.1016/S0092-8674(00)81683-9 · DOI · Paper page
- Hanahan, 2011, Hallmarks of cancer: the next generation, Cell, 144, 646, 10.1016/j.cell.2011.02.013 · DOI · Paper page
- Thomas, 1982, On immunosurveillance in human cancer, Yale J Biol Med, 55, 329
- Thomas, 1959, Discussion on Cellular and Humoral Aspects of the Hypersensitive States, 529
- Burnet, 1957, Cancer – a biological approach, Br Med J, 1, 779, 10.1136/bmj.1.5022.779 · DOI · Paper page
- Shankaran, 2001, IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity, Nature, 410, 1107, 10.1038/35074122 · DOI · Paper page
- Gatti, 1971, Occurrence of malignancy in immunodeficiency diseases. A literature review, Cancer, 28, 89, 10.1002/1097-0142(197107)28:189::AID-CNCR28202801173.0.CO;2-Q · doi:10.1002/1097-0142(197107)28:189::aid-cncr28202801173.0.co;2-q
- Birkeland, 1995, Cancer risk after renal transplantation in the Nordic countries, 1964-1986, Int J Cancer, 60, 183, 10.1002/ijc.2910600209 · DOI · Paper page
- Penn, 2000, Post-transplant malignancy: the role of immunosuppression, Drug Saf, 23, 101, 10.2165/00002018-200023020-00002 · DOI · Paper page
- Penn, 1995, Sarcomas in organ allograft recipients, Transplantation, 60, 1485, 10.1097/00007890-199560120-00020 · DOI · Paper page
- MacKie, 2003, Fatal melanoma transferred in a donated kidney 16 years after melanoma surgery, N Engl J Med, 348, 567, 10.1056/NEJM200302063480620 · DOI · Paper page
- Strauss, 2010, Transmission of donor melanoma by organ transplantation, Lancet Oncol, 11, 790, 10.1016/S1470-2045(10)70024-3 · DOI · Paper page
- Galon, 2006, Type, density, and location of immune cells within human colorectal tumors predict clinical outcome, Science, 313, 1960, 10.1126/science.1129139 · DOI · Paper page
- Chouaib, 2012, Hypoxia promotes tumor growth in linking angiogenesis to immune escape, Front Immunol, 3, 21, 10.3389/fimmu.2012.00021 · DOI · Paper page
- Ferrara, 1997, The biology of vascular endothelial growth factor, Endocr Rev, 18, 4, 10.1210/edrv.18.1.0287 · DOI · Paper page
- Dvorak, 1995, Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis harold, Am J Pathol, 146, 1029
- Dewerchin, 2012, PlGF: a multitasking cytokine with disease-restricted activity, Cold Spring Harb Perspect Med, 2, a011056, 10.1101/cshperspect.a011056 · DOI · Paper page
- Dikov, 2005, Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation, J Immunol, 174, 215, 10.4049/jimmunol.174.1.215 · DOI · Paper page
- Goel, 2013, VEGF targets the tumour cell, Nat Rev Cancer, 13, 871, 10.1038/nrc3627 · DOI · Paper page
- Hansen, 2012, Neuropilin 1 deficiency on CD4+Foxp3+ regulatory T cells impairs mouse melanoma growth, J Exp Med, 209, 2001, 10.1084/jem.20111497 · DOI · Paper page
- Koch, 2011, Signal transduction by vascular endothelial growth factor receptors, Biochem J, 437, 169, 10.1042/BJ20110301 · DOI · Paper page
- Banchereau, 1998, Dendritic cells and the control of immunity, Nature, 392, 245, 10.1038/32588 · DOI · Paper page
- Haux, 1997, Tumor-infiltrating dendritic cells are defective in their antigen-presenting function and inducible B7 expression in rats, Int J Cancer, 624, 619
- Almand, 2000, Clinical significance of defective dendritic cell differentiation in cancer, Clin Cancer Res, 6, 1755
- Gabrilovich, 1996, Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells, Nat Med, 2, 1096, 10.1038/nm1096-1096 · DOI · Paper page
- Oyama, 1998, Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hematopoietic progenitor cells, J Immunol, 160, 1224, 10.4049/jimmunol.160.3.1224 · DOI · Paper page
- Lin, 2007, Placental growth factor down-regulates type 1 T helper immune response by modulating the function of dendritic cells, J Leukoc Biol, 82, 1473, 10.1189/jlb.0307164 · DOI
- Alfaro, 2009, Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes, Br J Cancer, 100, 1111, 10.1038/sj.bjc.6604965 · DOI · Paper page
- Huang, 2007, Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF, Blood, 110, 624, 10.1182/blood-2007-01-065714 · DOI · Paper page
- Zea, 2004, l-Arginine modulates CD3zeta expression and T cell function in activated human T lymphocytes, Cell Immunol, 232, 21, 10.1016/j.cellimm.2005.01.004 · DOI · Paper page
- Rodriguez, 2007, l-arginine availability regulates T-lymphocyte cell-cycle progression, Blood, 109, 1568, 10.1182/blood-2006-06-031856 · DOI · Paper page
- Mazzoni, 2002, Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism, J Immunol, 168, 689, 10.4049/jimmunol.168.2.689 · DOI · Paper page
- Fischer, 2001, Activation of cGMP-dependent protein kinase Ibeta inhibits interleukin 2 release and proliferation of T cell receptor-stimulated human peripheral T cells, J Biol Chem, 276, 5967, 10.1074/jbc.M009781200 · DOI
- Kusmartsev, 2004, Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species, J Immunol, 172, 989, 10.4049/jimmunol.172.2.989 · DOI · Paper page
- Li, 2009, Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1, J Immunol, 182, 240, 10.4049/jimmunol.182.1.240 · DOI · Paper page
- Hoechst, 2009, Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor, Hepatology, 50, 799, 10.1002/hep.23054 · DOI · Paper page
- Gabrilovich, 1998, Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo, Blood, 92, 4150, 10.1182/blood.V92.11.4150 · DOI · Paper page
- Almand, 2001, Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer, J Immunol, 166, 678, 10.4049/jimmunol.166.1.678 · DOI · Paper page
- Huang, 2006, Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host, Cancer Res, 66, 1123, 10.1158/0008-5472.CAN-05-1299 · DOI · Paper page
- Yang, 2006, CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells, Cancer Res, 66, 6807, 10.1158/0008-5472.CAN-05-3755 · DOI · Paper page
- Serafini, 2008, Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells, Cancer Res, 68, 5439, 10.1158/0008-5472.CAN-07-6621 · DOI · Paper page
- Ghiringhelli, 2005, Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation, J Exp Med, 202, 919, 10.1084/jem.20050463 · DOI · Paper page
- Hanada, 2000, Prognostic value of tumor-associated macrophage count in human bladder cancer, Int J Urol, 7, 263, 10.1046/j.1442-2042.2000.00190.x · DOI · Paper page
- Lissbrant, 2000, Tumor associated macrophages in human prostate cancer: relation to clinicopathological variables and survival, Int J Oncol, 17, 445
- Salvesen, 1999, Significance of tumour-associated macrophages, vascular endothelial growth factor and thrombospondin-1 expression for tumour angiogenesis and prognosis in endometrial carcinomas, Int J Cancer, 84, 538, 10.1002/(SICI)1097-0215(19991022)84:5538::AID-IJC173.3.CO;2-2 · doi:10.1002/(sici)1097-0215(19991022)84:5538::aid-ijc173.3.co;2-2
- Leek, 1996, Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma, Cancer Res, 56, 4625
- Linde, 2012, Vascular endothelial growth factor-induced skin carcinogenesis depends on recruitment and alternative activation of macrophages, J Pathol, 227, 17, 10.1002/path.3989 · DOI · Paper page
- Lewis, 2007, Inflammation and breast cancer. Microenvironmental factors regulating macrophage function in breast tumours: hypoxia and angiopoietin-2, Breast Cancer Res, 9, 209, 10.1186/bcr1679 · DOI
- Ohm, 2003, VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression, Blood, 101, 4878, 10.1182/blood-2002-07-1956 · DOI · Paper page
- Prévost-Blondel, 1998, Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo, J Immunol, 161, 2187, 10.4049/jimmunol.161.5.2187 · DOI · Paper page
- Hermans, 1998, Antigen expressed on tumor cells fails to elicit an immune response, even in the presence of increased numbers of tumor-specific cytotoxic T lymphocyte precursors, Cancer Res, 58, 3909
- Lee, 1999, Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients, Nat Med, 5, 677, 10.1038/9525 · DOI · Paper page
- Romero, 1998, Ex vivo staining of metastatic lymph nodes by class i major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes, J Exp Med, 188, 10.1084/jem.188.9.1641 · DOI · Paper page
- Rosenberg, 2005, Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma, J Immunol, 175, 6169, 10.4049/jimmunol.175.9.6169 · DOI · Paper page
- Hamzah, 2008, Vascular normalization in Rgs5-deficient tumours promotes immune destruction, Nature, 453, 410, 10.1038/nature06868 · DOI · Paper page
- Ziogas, 2012, VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor Type 2, Int J Cancer, 130, 857, 10.1002/ijc.26094 · DOI · Paper page
- Gavalas, 2012, VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2, Br J Cancer, 107, 1869, 10.1038/bjc.2012.468 · DOI · Paper page
- Escudier, 2007, Sorafenib in advanced clear-cell renal-cell carcinoma, N Engl J Med, 356, 125, 10.1056/NEJMoa060655 · DOI · Paper page
- Miller, 2007, Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer, N Engl J Med, 357, 2666, 10.1056/NEJMoa072113 · DOI · Paper page
- Gabrilovich, 1999, Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function, Clin Cancer Res, 5, 2963
- Kusmartsev, 2008, Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma, J Immunol, 181, 346, 10.4049/jimmunol.181.1.346 · DOI · Paper page
- Xin, 2009, Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells, Cancer Res, 69, 2506, 10.1158/0008-5472.CAN-08-4323 · DOI · Paper page
- Cao, 2011, Kinase inhibitor Sorafenib modulates immunosuppressive cell populations in a murine liver cancer model, Lab Invest, 91, 598, 10.1038/labinvest.2010.205 · DOI
- Ko, 2009, Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients, Clin Cancer Res, 15, 2148, 10.1158/1078-0432.CCR-08-1332 · DOI · Paper page
- Abe, 2010, Therapeutic activity of sunitinib for Her2/neu induced mammary cancer in FVB mice, Int Immunopharmacol, 10, 140, 10.1016/j.intimp.2009.09.023 · DOI
- Chen, 2013, Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity, Int J Cancer, 134, 319, 10.1002/ijc.28362 · DOI
- Kujawski, 2010, Targeting STAT3 in adoptively transferred T cells promotes their in vivo expansion and antitumor effects, Cancer Res, 70, 9599, 10.1158/0008-5472.CAN-10-1293 · DOI
- Adotevi, 2010, A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients, J Immunother, 33, 991, 10.1097/CJI.0b013e3181f4c208 · DOI · Paper page
- Nagai, 2012, Sorafenib prevents escape from host immunity in liver cirrhosis patients with advanced hepatocellular carcinoma, Clin Dev Immunol, 2012, 607851, 10.1155/2012/607851 · DOI
- Shrimali, 2010, Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer, Cancer Res, 70, 6171, 10.1158/0008-5472.CAN-10-0153 · DOI · Paper page
- Terme, 2012, Modulation of immunity by antiangiogenic molecules in cancer, Clin Dev Immunol, 2012, 492920, 10.1155/2012/492920 · DOI
- Tartour, 2011, Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy, Cancer Metastasis Rev, 30, 83, 10.1007/s10555-011-9281-4 · DOI · Paper page
- Bose, 2011, Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination, Int J Cancer, 129, 2158, 10.1002/ijc.25863 · DOI
- Farsaci, 2012, Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy, Int J Cancer, 130, 1948, 10.1002/ijc.26219 · DOI
- Jaini, 2014, Combination of sunitinib with anti-tumor vaccination inhibits T cell priming and requires careful scheduling to achieve productive immunotherapy, Int J Cancer, 134, 1695, 10.1002/ijc.28488 · DOI
- Dall’Oglio, 2011, Early experience with targeted therapy and dendritic cell vaccine in metastatic renal cell carcinoma after nephrectomy, Int Braz J Urol, 37, 180, 10.1590/S1677-55382011000200004 · doi:10.1590/s1677-55382011000200004
- Bhatia, 2014, Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study, J Immunother Cancer, 2, 2, 10.1186/2051-1426-2-2 · DOI
Cited by
The biology and management of non-small cell lung cancer
Herbst, R. S., Morgensztern, D., & Boshoff, C. (2018) · Nature · doi:10.1038/nature25183 · Cited by 4,891
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448
Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Peng, W., Chen, J. Q., Liu, C., Malu, S., Creasy, C., Tetzlaff, M. T., Xu, C., McKenzie, J. A., Zhang, C., Liang, X., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0283 · Cited by 1,539
Zeng, D., Li, M., Zhou, R., Zhang, J., Sun, H., Shi, M., Bin, J., Liao, Y., Rao, J., & Liao, W. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0436 · Cited by 986
“These data offer mechanistic insights into the responses to immune-checkpoint blockade, suggesting that response to PD-L1 and PD-1 blockade is not only related to enhanced cytolytic activity, antigen processing, and IFNg pathway components (13, 75), but is also associated with inhibition of fibroblast activation, angi…”
BackgroundWallin, J. J., Bendell, J. C., Funke, R., Sznol, M., Korski, K., Jones, S., Hernandez, G., Mier, J., He, X., Hodi, F. S., et al. (2016) · Nature Communications · doi:10.1038/ncomms12624 · Cited by 713
Metadata
- Authors
- Voron, T., Marcheteau, E., Pernot, S., Colussi, O., Tartour, E., Taieb, J., & Terme, M.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2014-04-02
- Volume
- 4
- Pages
- 70-70
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W2169435545
- Cited by
- 325
- References
- 19
- FWCI
- 8.52
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Control of the Immune Response by Pro-Angiogenic Factors. https://app.cochat.ai/papers/10.3389/fonc.2014.00070
- The paper
- Voron, T., Marcheteau, E., Pernot, S., Colussi, O., Tartour, E., Taieb, J., & Terme, M. (2014). Control of the Immune Response by Pro-Angiogenic Factors. Frontiers in Oncology. https://doi.org/10.3389/fonc.2014.00070
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.